case of chronically progressive, often therapy-resistant pulmonary arterial hypertension (PAH). SERVICE For further information , please contact Professor Dr. Georg Hansmann, telephone (0511) 532-9594

approaches for both causes of cardiac injury, for which there is currently no specific treatment. SERVICE: For further information , please contact Professor Dr. Dr. Thomas Thum, thum.thomas@mh-hannover

s have already filed a patent application for the use of MYGDF as a new drug for heart failure. SERVICE: For further information , please contact Professor Dr. Kai Wollert, wollert.kai@mh-hannover.de

database of disease cases and collects biomaterial from affected individuals for scientific studies. SERVICE: The original paper can be found here .

already left the Medical School can submit an application to continue using the electronic library services and the RefWorks literature management program. The prerequisite for this is that the thesis has

confirmed in further studies in large animal models and later also in clinical studies in humans. SERVICE: For further information, please contact Dr. Christian Bär, baer.christian@mh-hannover.de , phone

after which initial results are expected. German Cancer Aid is funding the study with 750,000 euros. SERVICE: For further information, please contact PD Dr. med. Matthias Jentschke, Jentschke.Matthias@mh-hannover

Research and by the Canadian Institutes of Health Research and the Terry Fox Research Institute. SERVICE: For further information , please contact Professor Dr. Christian Kratz, telephone + 49 (511) 532-6712

within the framework of the Lung Ambition Alliance, a partnership between industry and science. SERVICE: For more information , please contact Professor Dr Jens Vogel-Claussen, scientific director of the

Laboratories for Biotechnology and Artificial Organs (LEBAO) under the direction of Dr. Ruth Olmer. SERVICE: For more information, contact Dr. Bettina Wiegmann, wiegmann.bettina@mh-hannover.de , phone (0511)